• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国肝细胞癌的流行病学

The Epidemiology of Hepatocellular Carcinoma in the USA.

作者信息

Kim Hyun-Seok, El-Serag Hashem B

机构信息

Section of Gastroenterology and Hepatology, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX, 77030, USA.

U.S. Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.

出版信息

Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. doi: 10.1007/s11894-019-0681-x.

DOI:10.1007/s11894-019-0681-x
PMID:30976932
Abstract

PURPOSE OF REVIEW

To discuss current knowledge and recent findings regarding the epidemiology of hepatocellular carcinoma (HCC) in the USA.

RECENT FINDING

The US incidence rate of HCC is increasing, although the pace may have somewhat slowed since 2010. In 2012, incidence rates of HCC in Hispanics surpassed those of Asians. The recent epidemiological changes in major risk factors for HCC include increasing hepatitis C virus post-sustained virologic response, suppressed hepatitis B virus on nucleoside analogues, and alcoholic and non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease has the greatest proportion of the burden of the main risk factors for HCC in the USA, followed by alcoholic liver disease, and hepatitis C virus and hepatitis B virus infections. This review focuses on current knowledge regarding the recent epidemiological trends in HCC, with an emphasis on future directions.

摘要

综述目的

讨论美国肝细胞癌(HCC)流行病学的当前知识和最新发现。

最新发现

美国HCC发病率呈上升趋势,尽管自2010年以来增速有所放缓。2012年,西班牙裔HCC发病率超过了亚裔。HCC主要危险因素最近的流行病学变化包括丙型肝炎病毒持续病毒学应答后发病率上升、核苷类似物抑制乙型肝炎病毒以及酒精性和非酒精性脂肪性肝病。在美国,非酒精性脂肪性肝病在HCC主要危险因素负担中所占比例最大,其次是酒精性肝病、丙型肝炎病毒和乙型肝炎病毒感染。本综述重点关注HCC近期流行病学趋势的当前知识,并强调未来方向。

相似文献

1
The Epidemiology of Hepatocellular Carcinoma in the USA.美国肝细胞癌的流行病学
Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. doi: 10.1007/s11894-019-0681-x.
2
Epidemiology and Management of Hepatocellular Carcinoma.原发性肝癌的流行病学和管理。
Gastroenterology. 2019 Jan;156(2):477-491.e1. doi: 10.1053/j.gastro.2018.08.065. Epub 2018 Oct 24.
3
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?丙型肝炎病毒时代的肝细胞癌:我们是否应该改变范式?
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940. doi: 10.3748/wjg.v25.i29.3929.
4
[Alcoholic liver diseases in Japan and modification by hepatitis virus].[日本的酒精性肝病及肝炎病毒的影响]
Nihon Arukoru Yakubutsu Igakkai Zasshi. 2003 Oct;38(5):403-14.
5
[Hepatocellular carcinoma: Increase in incidence or future plague?].[肝细胞癌:发病率上升还是未来的祸患?]
Bull Cancer. 2018 May;105(5):502-507. doi: 10.1016/j.bulcan.2018.02.003. Epub 2018 Mar 19.
6
[Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis].[慢性病毒性肝炎中的抗病毒治疗与肝细胞癌风险]
Ter Arkh. 2013;85(10):94-7.
7
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.从肝癌的诊断到治疗:发达国家和发展中国家共同面临的流行问题。
World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282.
8
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.美国肝细胞癌风险因素的人群归因分数
Cancer. 2016 Jun 1;122(11):1757-65. doi: 10.1002/cncr.29971. Epub 2016 Mar 21.
9
Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?美国肝癌发病率和人口统计学的上升:这意味着什么?
Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):365-70. doi: 10.1586/egh.11.20.
10
Epidemiology and clinical presentation of hepatocellular carcinoma.肝细胞癌的流行病学与临床表现
J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S169-71. doi: 10.1016/s1051-0443(07)61783-7.

引用本文的文献

1
Risk of malignancy in adult patients with congenital heart disease: a clinical practice review.成人先天性心脏病患者的恶性肿瘤风险:一项临床实践综述
Cardiovasc Diagn Ther. 2025 Feb 28;15(1):195-206. doi: 10.21037/cdt-24-388. Epub 2025 Feb 25.
2
Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease.他汀类药物的使用与慢性肝病患者肝细胞癌及肝纤维化风险
JAMA Intern Med. 2025 May 1;185(5):522-530. doi: 10.1001/jamainternmed.2025.0115.
3
Macrotrabecular-Massive Hepatocellular Carcinoma: A Case Report.

本文引用的文献

1
Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection.美国高感染风险成年人中乙型肝炎病毒疫苗诱导免疫不可检测的流行率。
Hepatology. 2019 Apr;69(4):1385-1397. doi: 10.1002/hep.30285. Epub 2019 Feb 20.
2
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.美国 1999-2016 年因肝硬化和肝癌导致的死亡率:观察性研究。
BMJ. 2018 Jul 18;362:k2817. doi: 10.1136/bmj.k2817.
3
Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
巨小梁-大块型肝细胞癌:一例报告
Cureus. 2024 Dec 19;16(12):e75989. doi: 10.7759/cureus.75989. eCollection 2024 Dec.
4
New Insights into the Pathogenesis of Alcoholic Liver Disease Based on Global Research.基于全球研究对酒精性肝病发病机制的新见解
Dig Dis Sci. 2025 Mar;70(3):903-918. doi: 10.1007/s10620-024-08778-y. Epub 2025 Jan 13.
5
Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report.晚期肝细胞癌停用VEGF抑制剂后单纯免疫治疗获得完全缓解:一例报告
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):246-250. doi: 10.5005/jp-journals-10018-1455. Epub 2024 Dec 27.
6
Impact of Screening on Mortality for Patients Diagnosed with Hepatocellular Carcinoma in a Safety-Net Healthcare System: An Opportunity for Addressing Disparities.在安全网医疗系统中,筛查对肝细胞癌确诊患者死亡率的影响:解决差异的契机。
Cancers (Basel). 2024 Nov 14;16(22):3829. doi: 10.3390/cancers16223829.
7
Immunotherapy Responses in Viral Hepatitis-Induced HCC: A Systematic Review and Meta-Analysis.免疫疗法治疗病毒性肝炎相关 HCC 的反应:系统评价和荟萃分析。
Curr Oncol. 2024 Nov 15;31(11):7204-7225. doi: 10.3390/curroncol31110532.
8
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.钇-90放射性栓塞治疗肝细胞癌的策略
World J Radiol. 2024 Oct 28;16(10):512-527. doi: 10.4329/wjr.v16.i10.512.
9
Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.丙型肝炎相关肝细胞癌肝移植中的种族差异
Ann Surg Oncol. 2025 Jan;32(1):426-437. doi: 10.1245/s10434-024-16317-2. Epub 2024 Oct 16.
10
Disparities in hepatitis C among people aged 12-59 with no history of injection drug use, United States, January 2013-March 2020.2013 年 1 月至 2020 年 3 月期间,美国无注射吸毒史的 12-59 岁人群中的丙型肝炎差异。
Liver Int. 2024 Dec;44(12):3250-3259. doi: 10.1111/liv.16108. Epub 2024 Sep 26.
慢性肝病病因相关年度死亡率的变化趋势:2007 年至 2016 年。
Gastroenterology. 2018 Oct;155(4):1154-1163.e3. doi: 10.1053/j.gastro.2018.07.008. Epub 2018 Sep 1.
4
Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program.全民疫苗接种计划启动30年后台湾地区乙肝病毒血清流行率
PeerJ. 2018 Feb 16;6:e4297. doi: 10.7717/peerj.4297. eCollection 2018.
5
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者肝胆癌的监测。
Hepatology. 2018 Jun;67(6):2338-2351. doi: 10.1002/hep.29730. Epub 2018 Apr 19.
6
Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.美国非酒精性脂肪性肝病患病率、严重程度和结局的种族和民族差异:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2018 Feb;16(2):198-210.e2. doi: 10.1016/j.cgh.2017.09.041. Epub 2017 Sep 29.
7
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.2型糖尿病与肝细胞癌风险:聚焦非酒精性脂肪性肝病
Ann Transl Med. 2017 Jul;5(13):270. doi: 10.21037/atm.2017.04.41.
8
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
9
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.在慢性乙型肝炎的白种人群中,恩替卡韦或替诺福韦治疗 5 年后肝癌风险降低。
Hepatology. 2017 Nov;66(5):1444-1453. doi: 10.1002/hep.29320. Epub 2017 Oct 11.
10
Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.美国乙肝病毒感染率及免疫率方面的种族/族裔差异。
J Viral Hepat. 2017 Nov;24(11):1052-1066. doi: 10.1111/jvh.12735. Epub 2017 Jul 3.